Ionis Pharmaceuticals, Inc. (IONS): Price and Financial Metrics

IONS POWR Grades

• Quality is the dimension where IONS ranks best; there it ranks ahead of 96.89% of US stocks.
• The strongest trend for IONS is in Growth, which has been heading up over the past 179 days.
• IONS's current lowest rank is in the Momentum metric (where it is better than 8.18% of US stocks).

IONS Stock Summary

• IONS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 232.04 -- higher than 89.27% of US-listed equities with positive expected earnings growth.
• Price to trailing twelve month operating cash flow for IONS is currently 167.82, higher than 97.2% of US stocks with positive operating cash flow.
• Of note is the ratio of Ionis Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 9.43% of US stocks have a lower such ratio.
• Stocks that are quantitatively similar to IONS, based on their financial statements, market capitalization, and price volatility, are ATRA, FGEN, RAPT, NTLA, and RNA.
• IONS's SEC filings can be seen here. And to visit Ionis Pharmaceuticals Inc's official web site, go to www.ionispharma.com.

IONS Valuation Summary

• IONS's price/sales ratio is 8.2; this is 115.79% higher than that of the median Healthcare stock.
• IONS's price/sales ratio has moved down 11.1 over the prior 243 months.
• Over the past 243 months, IONS's price/sales ratio has gone down 11.1.

Below are key valuation metrics over time for IONS.

IONS Growth Metrics

Its 4 year price growth rate is now at 61.87%.
• Its 4 year net cashflow from operations growth rate is now at 2050%.
• The 5 year net cashflow from operations growth rate now stands at 2050%.

IONS's revenue has moved down $122,208,000 over the prior 15 months.

The table below shows IONS's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-12-31	810.456	30.799	-28.597
2021-09-30	660.731	-74.911	-593.481
2021-06-30	687.717	-29.694	-541.959
2021-03-31	707.504	-11.186	-492.929
2020-12-31	729.264	35.892	-451.286
2020-09-30	932.664	215.847	73.401

IONS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• IONS has a Quality Grade of C, ranking ahead of 48.06% of graded US stocks.
• IONS's asset turnover comes in at 0.277 -- ranking 161st of 682 Pharmaceutical Products stocks.
• EDIT, MYMD, and VSTM are the stocks whose asset turnover ratios are most correlated with IONS.

The table below shows IONS's key quality metrics over time.